We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Oruba Presents State-of-the-Art Self-Operating Uroflowmeters

By LabMedica International staff writers
Posted on 15 Nov 2023

Image: Oruba Technology is showcasing the future of urology at MEDICA 2023 (Photo courtesy of Oruba)

Image: Oruba Technology is showcasing the future of urology at MEDICA 2023 (Photo courtesy of Oruba)

Oruba Technology & Innovation (Langenfeld, Germany) is demonstrating its state-of-the-art self-operating uroflowmeters at MEDICA 2023.

Oruba is showcasing Oruflow, the world’s first self-operating uroflowmeter. As a point-of-care diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere. The self-cleaning and hygienic point-of-care solution has revolutionized the process of uroflowmetry, making it a crucial part of every hospital and urology clinic. The self-operating uroflowmeter can be operated in easy steps. The patient first has to scan the hospital barcode to start the examination. The on-board screen helps the patients and guides them during the examination. Oruba Oruﬂow measures the test parameters and prepares the report. The patient then uses the hospital barcode to let Oruba Oruﬂow save the examination report into the hospital information system automatically. The patient can receive the results of the examination in seconds without any operator guidance.

As soon as the urination ﬁnishes, Oruba Oruﬂow prints the results out and cleans itself automatically. The patient can go to the doctor directly and the device gets ready for the next examination in one minute. Oruba Oruﬂow does not require an operator or nurse guidance and the patient does the test in an actual restroom comfort. Oruba Oruﬂow technology creates a hygienic and relaxed clinical atmosphere and prevents the unpleasant smell and dirt problem. Oruba Oruﬂow’s high-developed IoT technology and auto-notiﬁcation system allows it to provide online technical service and solve the problem in minutes. The yearly maintenance and software upgrades are done from the Oruba HQ

Related Links:
Oruba Technology & Innovation

Visit expo >

New

Gold Member

Aspiration System

VACUSAFE

New

Gold Member

Neonatal Heel Incision Device

Tenderfoot

New

Rapid Sepsis Test

SeptiCyte RAPID

New

CMV CLIA Diagnostic

CLIA CMV IgA Screen Group

Latest Medica 2023 News

Channels

Clinical Chemistry

view channel

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Image: ApoB is a blood test that counts the total number of harmful particles in circulation, providing a more complete assessment of risk (photo courtesy of Adobe Stock)

Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy

Routine blood tests that measure low-density lipoprotein (LDL), commonly known as “bad” cholesterol, are widely used to guide lipid-lowering therapy, but they do not always provide a complete picture of... Read more

Image: Overview of the dual-mode xVFA optical sensor platform for multiplexed cardiac biomarker detection in point-of-care settings (Han, GR., Eryilmaz, M., Goncharov, A. et al. Light Sci Appl 15, 190 (2026). doi.org/10.1038/s41377-026-02275-9)

AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers

Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read more

Molecular Diagnostics

view channel

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more

Image: Graphical abstract (Robinson S, Haile B, Reily-Bell M et al, Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.102744)

Blood Test Enables Early Detection and Classification of Glioma

High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more

Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types

Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more

Image: MyGenius PRO installed at a leading European transplant center supporting routine infectious disease testing (photo courtesy of Bruker)

New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing

Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read more

Hematology

view channel

Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality

Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more

Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer

Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more

New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy

Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more

Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers

Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more

Immunology

view channel

Image: Graphical abstract - Human immune aging clock identifies RUNX1 as a decelerator of T cell senescence (photo courtesy of Zhang Weiqi)

Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target

Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more

Study Finds Influenza Often Undiagnosed in Winter Deaths

Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read more

Combined Screening Approach Identifies Early Leprosy Cases

Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more

Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Microbiology

view channel

Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections

Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read more

Antibiotic Resistance Genes Found in Newborns Within Hours of Birth

Antibiotic resistance in early life is challenging to characterize, particularly around the timing and drivers of gene acquisition in newborns. Meconium, the first stool passed by infants, was long considered... Read more

mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels

Central nervous system (CNS) infections such as encephalitis, ventriculitis, and brain abscess are among the most time-sensitive diagnostic challenges in neurology. Standard testing can return negative... Read more

Image: Professor Rajesh Ramanathan, from the Sir Ian Potter NanoBioSensing Facility and NanoBiotechnology Research Laboratory in RMIT’s School of Science, and Dr Pabudi Weerathunge examine colour changes during a laboratory test used to identify golden staph strains (photo courtesy of Will Wright, RMIT University)

Rapid Color Test Stratifies Virulent and Resistant Staph Strains

Staphylococcus aureus (golden staph) remains a leading cause of infection-related mortality worldwide, responsible for more than a million deaths each year. Rapidly distinguishing highly virulent or a... Read more

Pathology

view channel

AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides

Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more

Image: Immunofluorescence staining showing that overexpression of WWOX (green) in A431 cells is associated with increased levels of p63 (red) (photo courtesy of Tirza Bidnay-Mizrahi)

Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer

Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read more

Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer

Colorectal cancer is common and often lethal, and therapeutic decision-making is complicated by heterogeneous tumor microenvironments. Immunotherapy benefits only a small subset of patients, around 5%,... Read more

Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates

Antibody-drug conjugates (ADC) are reshaping oncology, yet scalable biomarkers that reliably predict which patients will benefit remain limited as treatment regimens and combinations grow more complex.... Read more

Technology

view channel

AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer

Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more

Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing

Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read more

Noninvasive Sputum Test Detects Early Lung Cancer

Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more

Image: Graphical Abstract (Huiqian Hu et al., Med 7(3): 100966 (2026). DOI: 10.1016/j.medj.2025.100966)

New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia

Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more

Industry

view channel

Image: The acquisition adds the LEX VELO System to QuidelOrtho’s portfolio (photo courtesy of LEX Diagnostics)

QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition

QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more

Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID

Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more